uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Clinical Neurophysiology.
Show others and affiliations
2015 (English)In: Experimental Neurology, ISSN 0014-4886, E-ISSN 1090-2430, Vol. 270, no SI, 29-40 p.Article in journal (Refereed) Published
Abstract [en]

Muscle-specific tyrosine kinase (MuSK) autoantibodies are the hallmark of a form of myasthenia gravis (MG) that can challenge the neurologist and the experimentalist. The clinical disease can be difficult to treat effectively. MuSK autoantibodies affect the neuromuscular junction in several ways. When added to muscle cells in culture, MuSK antibodies disperse acetylcholine receptor clusters. Experimental animals actively immunized with MuSK develop MuSK autoantibodies and muscle weakness. Weakness is associated with reduced postsynaptic acetylcholine receptor numbers, reduced amplitudes of miniature endplate potentials and endplate potentials, and failure of neuromuscular transmission. Similar impairments have been found in mice injected with IgG from MG patients positive for MuSK autoantibody (MuSK-MG). The active and passive models have begun to reveal the mechanisms by which MuSK antibodies disrupt synaptic function at the neuromuscular junction, and should be valuable in developing therapies for MuSK-MG. However, translation into new and improved treatments for patients requires procedures that are not too cumbersome but suitable for examining different aspects of MuSK function and the effects of potential therapies. Study design, conduct and analysis should be carefully considered and transparently reported. Here we review what has been learnt from animal and culture models of MuSK-MG, and offer guidelines for experimental design and conduct of studies, including sample size determination, randomization, outcome parameters and precautions for objective data analysis. These principles may also be relevant to the increasing number of other antibody-mediated diseases that are now recognized.

Place, publisher, year, edition, pages
2015. Vol. 270, no SI, 29-40 p.
National Category
URN: urn:nbn:se:uu:diva-247315DOI: 10.1016/j.expneurol.2014.12.013ISI: 000356563800005PubMedID: 25542979OAI: oai:DiVA.org:uu-247315DiVA: diva2:795908
Available from: 2015-03-17 Created: 2015-03-17 Last updated: 2015-07-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Punga, Anna Rostedt
By organisation
Clinical Neurophysiology
In the same journal
Experimental Neurology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 329 hits
ReferencesLink to record
Permanent link

Direct link